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Introduction
Worldwide, an estimated 240 million people are chronically infected with hepatitis B, which accounts for around 45% of cases of hepatocellular carcinoma and 30% of cirrhosis (Papatheodoridis et al., 2015) . Perinatal transmission is the major route of hepatitis B virus (HBV) transmission. To reduce the risk of mother-to-infant transmission, American Association for the Study of Liver Diseases recommends the pregnant women with an HBV DNA level > 200,000 IU/ml to be treated with nucleoside analogues (NAs) (Terrault et al., 2016) . Currently, tenofovir, entecavir, emtricitabine, telbivudine, lamivudine and adefovir have been applied to hepatitis B treatment; however, none of them are approved for use in pregnancy. (Lok et al., 2016) . Women of reproductive age with hepatitis B infection or women already on therapy in pregnancy have to face the drug safety issue on the fetus (Giles et al., 2011) . Lamivudine is the most used antivirals but with high risk of viral resistance, while tenofovir and telbivudine, classified as pregnancy category B drugs, were also reported with nephron-toxicity and rhabdomyolysis (Woodward et al., 2009; Zou et al., 2011; Hermans et al., 2016) . It was reported that tenofovir would lower bone mineral content in infants if it was applied in late pregnancy (Siberry et al., 2015) . Therefore, it is necessary to explore other potential antivirals to treat HBV infection in pregnancy.
Entecavir (ETV) is a synthetic deoxyguanosine analog, approved in 2005 by US Food
and Drug Administration, and has been the first-line antiviral agent in general population based on the high potency against HBV and significant barrier to drug resistance (Hosaka et al., 2013) . However, the safety of ETV in pregnancy has not reached consensus. To clarify whether ETV could be applied in pregnancy, it is essential to investigate whether ETV will cross the placental barrier which interferes with drug delivery to fetus (Prouillac and Lecoeur, 2010) . ETV is a hydrophilic compound with a pKa value of This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on January 6, 2017 as DOI: 10.1124/dmd.116.073304 at ASPET Journals on September 21, 2017 dmd.aspetjournals.org Downloaded from 10.5, which implies that it is unlikely to cross the placenta by passive diffusion. However, various drug transporters, including solute carrier (SLC) transporters and ATP-binding cassette (ABC) transporters located in the single layer of polarized syncytiotrophoblasts in placenta, may mediate the ETV permeation across the placental barrier. Organic cation transporter (OCT) 3 and organic anion transporter (OAT) 4 are the highest OCTs and OATs in placenta, respectively. OCT3 and OAT4 are reported in basal side of the trophoblasts, which contribute to the transport of substrate drugs from fetus to placenta (Ugele et al., 2003; Lee et al., 2013a) . Organic cation/carnitine transporter (OCTN) 1/2 are also expressed in human placenta, which may mediate the uptake of drugs from maternal blood into trophoblasts (Lahjouji et al., 2004; Grube et al., 2005) .
P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) 2 and breast cancer resistance protein (BCRP) are expressed in maternal side of the trophoblast layer and mediate drugs from fetal to maternal circulation (Pollex and Hutson, 2011; Berveiller et al., 2015) . Previous researches on ETV renal clearance in vivo indicated that OAT1/3, OCT2 and peptide transporter (PEPT) 2 might be involved in the renal secretion and reabsorption of ETV (Chen et al., 2011; Xu et al., 2014) . However, scant information is available with respect to the transporters involved in the placental transfer of ETV.
The aim of this study was to explore whether ETV could cross the human placenta and the underlying mechanism based on the role of drug transporters. Firstly, we studied placental permeation of ETV in pregnant mice to evaluate the fetal exposure of ETV.
Secondly, we clarified which transporters were involved in placental transfer of ETV in forskolin treated or untreated BeWo cells (a human choriocarcinoma cell line), cell models high expressing the specific transporters, and primary human trophoblast cells.
The results will provide the useful information to elucidate whether ETV could be applied in the pregnant women.
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Materials and methods
Materials
Fetal bovine serum (FBS), trypsin, Kaighn's Modification of medium and Dulbecco's modified Eagle medium (DMEM) were from GIBCO (Invitrogen Life Technologies, USA). MK-571, Ko143, rhodamine123 and 6-carboxyl fluorescein (6-CF) were obtained from Sigma-Aldrich (St. Louis, MO, USA). L-carnitine, L-ergothioneine, adenosine, phlorizin, 5-hydroxytryptamine (5-HT) and forskolin were from Aladdin Co., Ltd (Shanghai, China). Entecavir, cytidine, guanosine and uridine were provided by Meilun biological Co., Ltd. (Dalian, China). Bicinchoninic acid (BCA) protein assay kit was from Beyotime Institute of Biotechnology (Beyotime, China).
Acetonitrile was obtained from Tedia (Fairfield, TX, USA). All other chemicals were of analytical grade.
Blank vector (pEnter), hCNT2 (SLC28A2) expression plasmid, hCNT3 (SLC28A3) expression plasmid and hOAT4 (SLC22A11) expression plasmid was obtained from ViGene Biosciences Inc. (Vigene, Shandong, China.)
Animals and the placental transfer of ETV in pregnant mice
Adult (8 -10 week of age) specific pathogen free wild-type ICR mice were obtained from the Experimental Animal Center of the Zhejiang Academy of Medical Sciences, and housed in the specific-pathogen-free facility in the Zhejiang University. The experimental procedures were approved by the Institutional Animal Care and Use Committee of Zhejiang University Medical Center. To obtain pregnant mice, we performed timed mating and checked the female early the following morning. The date that a vaginal plug observed was assigned as gestational day 0.5 (E=0.5). After overnight fast at E19.5, pregnant mice were administered with ETV by gavage at the dosage of 0.833 µg/g. The maternal blood samples (0.25 mL) were collected from the orbital venous sinus to This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on January 6, 2017 as DOI: 10.1124/dmd.116.073304 at ASPET Journals on September 21, 2017 dmd.aspetjournals.org Downloaded from heparinized tubes at 0.25, 1.0 and 4.0 h post-dosing, and the fetal blood samples were collected immediately after fetuses were sacrificed. The plasma was collected immediately after centrifugation at 8000 g for 10 min and then stored at -80°C until analysis.
Cell culture and transfection
BeWo cells were kindly provided by Prof. Ximei Wu, Zhejiang University School of Medicine, and cultured in F12K medium supplemented with 15% FBS, and 1% penicillin/streptomycin in a humidified air / CO 2 incubator (5% v/v) at 37°C. The MDCK cells stably transfected with full length hOCT3 cDNA (MDCK-hOCT3) and Lilly Laboratories Cell-Porcine Kidney 1 (LLC-PK1) cells stably transfected with full length hBCRP cDNA (LLC-PK1-hBCRP) were established or kept in our laboratory (Tian et al., 2013; Sun et al., 2014 
ETV accumulation in primary human trophoblast cells (PHTCs)
Placental cytotrophoblasts cells were isolated from human uncomplicated placentae delivered at term (38 -40 weeks) as the method reported previously with minor modifications (Wang et al., 2012) . Briefly, villous from the maternal surface was cut away from vessels. The tissue was minced and transferred to 200 mL DMEM contained 25 mM glucose (DMEM-H-G) containing 0.07% trypsin (Gibico) and 0.2 mg/ml DNase I (Sigma; ≥ 400 Kunitz units/mg protein). The mixture was incubated in a shaking water bath for digestion for four times successively with 30, 40, 15 and 15 min each, and the third and fourth digestion were used to collect pellets after centrifuging at 1340 g for 10 min. The pellets were re-suspended in 10 ml DMEM-H-G, which was layered over a 5%
to 65% Percoll gradient solution at step increments of 5%, and centrifuged at 1340 g for 20 min. After centrifugation, the middle layer containing cytotrophoblasts were removed to another tube and washed once with DMEM-H-G, and re-suspended subsequently in This article has not been copyedited and formatted. The final version may differ from this version. The syncytiotrophoblasts were spontaneously syncytialized from cytotrophoblasts after 72 h cultivation, and then the accumulation assay was performed as the method for
BeWo cells.
Quantification of ETV by LC-MS/MS
The quantification of ETV in cell lysates was determined by an Agilent 1290-6460
LC-MS with a triple quadrupole mass spectrometer (Agilent, CA, USA) as the method established in our lab .
The concentration of ETV in plasma was determined as the method above with a minor modification. Briefly, 600 μ l acetonitrile containing 10 nM of phenacetin (internal standard) were added to 100 µl of the plasma for protein precipitation. After vortexing for 5 min, the mixture was centrifuged at 16000 g for 15 min, and 600 
Statistical analysis
The data were presented as mean ± standard deviation (SD) in triplicate of at least two independent experiments. One-way analysis of variance (ANOVA) followed by Dunnett significant difference test and unpaired Student's t-test were performed using GraphPad Prism version 5.0 (GraphPad Software Inc., San Diego, CA). A value of P < 0.05 was considered to be significant.
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
The placental transfer of ETV in pregnant mice
To study whether ETV could cross the mouse placenta, the concentrations of ETV in the maternal and fetal plasma were determined. According to the pharmacokinetic characteristics in human, the plasma concentration of ETV reached maximum at 0.5-1.5 h after oral administration of 1 mg ETV /individual (Scott and Keating, 2009 ). The plasma concentration was determined at 0.25, 1.0 and 4.0 h post-dosing with ETV at 0.833 µg/g mouse body weight. As shown in Fig. 1 , the mean concentrations of ETV were 87.7, 96.0 and 10.7 ng/ml in maternal plasma, and 2.1, 17.4 and 6.8 ng/ml in fetal plasma, respectively. The mean fetal to maternal concentration ratio of ETV was 2.9 %, 25.6%
and 72.9%, respectively.
ETV accumulation in BeWo cells
BeWo 2B ). In addition, the accumulation (2 min) was increased within the concentration from 5 to 2000 µM. ETV uptake in activated BeWo cells was higher than that in non-activated cells within 20 µM but not at higher concentrations (Fig. 2C) .
Roles of uptake and efflux transporters in ETV accumulation in BeWo cells
Since ETV was reported to be a substrate of hPEPT2 (Xu et al., 2014) and mRNA This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 3A) .
Placenta also expresses the efflux transporters, such as P-gp, MRP2 and BCRP. Our results showed verapamil (100 µM) or GF120918 (10 µM), MK571 (50 µM) and Ko143
(5 µM), the inhibitors of P-gp, MRP2 and BCRP, respectively, increased ETV accumulation in BeWo cells (Fig. 3B ), which suggests that P-gp, MRP2 and BCRP might contribute to the ETV efflux from the cells. Although mRNA expression of P-gp in BeWo cells was fairly low, the accumulation of rhodamin 123 (a substrate of P-gp) was significantly inhibited by verapamil and GF120918, indicating that P-gp is functionally expressed in BeWo cells (Fig. 3C ). In addition, ETV accumulation (5 µM, 1h) in LLC-PK1-hBCRP cells was 63% of that in mock cells, and GF120918 (10 µM) markedly increased ETV accumulation in LLC-PK1-hBCRP cells further confirmed that ETV was a substrate of BCRP (P < 0.01) (Fig. 3D) .
Nucleoside transporters played roles in the uptake of ETV in BeWo cells
The Fig. 2A) , we speculated that the NTs might play significant roles in the uptake of ETV in BeWo cells. To test our speculation, the effects of Na + and S-(4-Nitrobenzyl)-6-thioinosine (NBTI) (an ENT-specific inhibitor) on ETV accumulation in BeWo cells were studied. Our data demonstrated that NBTI markedly reduced ETV accumulation in non-activated BeWo cells at 100 µM (a concentration at which ENT1 and ENT2 were inhibited completely), but not at 1 µM (a concentration at which ENT1 but not ENT2 could be inhibited). The inhibition of NBTI (100 µM) was aborted in activated BeWo cells (Fig. 4A) , which was consistent with decreased mRNA expression of ENT2 ( Fig. 2A) . Moreover, 100 µM of adenosine and cytidine (inhibitors of NTs) and 200 µM of phlorizin (a CNT2/3 inhibitor) strongly inhibited the ETV accumulation both in activated and non-activated BeWo cells. In addition, Na + free buffer reduced ETV accumulation to 66% and 25% of the control, respectively, in activated and non-activated BeWo cells (Fig. 4A) . The results above strongly indicate that CNTs, sodium-dependent transporters, play key roles in ETV uptake in BeWo cells. The accumulation of other antivirals like adefovir, emtricitabine and tenofovir was much lower than that of ETV (data not shown). The NBTI inhibited the uptake of emtricitabine, and the accumulation of adefovir was slightly reduced in Na + free buffer, whereas neither NBTI nor Na + free buffer affected the accumulation of tenofovir in non-activated BeWo cells (Fig. 4B) .
ETV was confirmed to be a substrate of hCNT2/3
To further confirm the contribution of hCNT2/3 to ETV transport, ETV uptake was hCNT2/3) and mRNA expression level ( Fig. 5A and Fig. 5B ). The accumulation of ETV (10 µM, 5 min) in MDCK-hCNT2 and MDCK-hCNT3 was 4 and 34 folds of that in mock cells, which could be significantly inhibited by 200 µM of phlorizin ( Fig. 5C and Fig. 5D ). ETV accumulation in MDCK-hCNT3 followed typical dynamics, and the Km and Vmax values were 23.1 µM and 0.3 nmol/mg protein/min, respectively (Fig. 5F) 
hOCT3 contributed to the transport of ETV while hOAT4 not
ETV was reported to be a substrate of OAT1 and OAT3 (Xu et al., 2013) . Considering the overlap of substrates for OATs and the high expression of OAT4 in placenta, we speculated that OAT4 might be involved in the transport of ETV in human placenta.
However, our results revealed the accumulation of ETV in HEK293-hOAT4 cells was not different with that in mock cells, although ETV (100 µM) inhibited the accumulation of 6-CF (20 µM, 5 min), a typical substrate of OAT, in HEK293-hOAT4 cells (P < 0.01) (Fig. 6B ).
Because hOCT3 is high expressed in human placenta, but it is rarely expressed in BeWo cells, we applied MDCK-hOCT3 cells to study whether hOCT3 would mediate ETV transport. ETV (100 µM) and D22 (4 µM, an inhibitor of OCT3) significantly (P <
0.001) inhibited the accumulation of 5-HT (a substrate of OCT3). ETV accumulation in
MDCK-hOCT3 cells was 1.7 folds of that in mock cells (Fig. 6D ), which could also be reduced by D22. The above results indicate that ETV is a substrate of OCT3, which imply that OCT3 is likely to mediate ETV transport in placenta.
Inhibition of ETV uptake into PHTCs
To further confirm and predict whether ETV could transport across human placenta, 
Discussion
This study investigated the trans-placental passage of ETV and the underlying mechanism, and found that only small amount of ETV crossed mouse placenta, indicating fetal exposure of ETV in human might be very low. The study further reveals that the SLC transporters, including CNT2/3, ENT1/2, OCTN2 and OCT3, and the ABC transporters, including P-gp, BCRP and MRP2 might contribute to ETV transport across human placenta.
Tenofovir and lamivudine, for treatment of HBV as well as immunodeficiency virus infection, could permeate human placenta in immunodeficiency virus-infected women with the median ratio of cord to maternal blood 60-70% and almost 100%, respectively (Mandelbrot et al., 2001; Hirt et al., 2009a; Mirochnick et al., 2014) . Our study showed the ratio of fetal to maternal plasma concentration of ETV was 2.9%, 25.6% and 72.9% at 0.25,1.0 and 4.0 h after dosing, respectively (Fig. 1) . However, the absolute concentration in fetal plasma was lower than 22.7 ng/ml. In consideration of the low therapeutic dose of ETV (0.5 mg/day) and similar overall structures between mice and human (Watson and Cross, 2005) , we deduced that the fetal exposure of ETV in human is very low.
The cellular accumulation of ETV in BeWo cells at 37°C was extremely higher than that at 4°C within 60 min ( Fig. 2B and 2C ), which strongly suggests that transporters are involved in the ETV uptake. ETV accumulation was increased at concentrations up to 2000 µM but without saturation. We speculated some transporters like ENT1/2 mediated ETV uptake characterized by atypical dynamics similar to ETV accumulation in MDCK-hCNT2 (Fig. 5E) . Interestingly, ETV accumulation in non-activated BeWo cells was decreased after 60 min at 37°C (Fig. 2B) , thus we deduce that some efflux This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 3B) . Moreover, ETV was proved to be a substrate of BCRP in present study and a substrate of P-gp and MRP2 in our lab . Together with the high expressions of P-gp, BCRP and MRP2
in human placenta and their location in apical membrane, we deduce that they may contribute to ETV transport from trophoblast cells to maternal blood. The efflux transporters, P-gp, BCRP and MRP2, were expressed in PHTCs (Fig. 7D) . Unexpectedly, the inhibitors of P-gp, BCRP and MRP2 did not increase the ETV accumulation in PHTCs (Fig. 7B ), which were not consistent with the results in BeWo cells (Fig. 3B ).
The exact reasons for the inconsistent results in BeWo cells and PHTCs were not clearly clarified. We speculated that the roles of efflux transporters might be eclipsed because of the co-existed high-affinity influx transporters which mediated ETV into PHTCs.
BeWo cells consists of most cytotrophoblasts and few syncytialized cells under non-activated condition, and could be induced by forskolin and differentiated to syncytiotrophoblasts. In terms of fetal-maternal barrier, it is mainly the syncytialized trophoblasts. Therefore, the activated BeWo cells are more appropriate to be used as an in vitro model to mimic drug placental transfer. ETV (5 μ M) accumulation in non-activated
BeWo was higher than that in activated BeWo (Fig. 2B ), however this difference was not obvious at higher concentrations (Fig. 2C) , which might be attributed to the saturation of some transporters with high affinity like CNT3. The result of ETV accumulation in the non-activated BeWo cells indicates ENT2 and CNT3 contribute to ETV uptake based on the mRNA expressions of NTs. The mRNA expressions of ENT2 and CNT3 were decreased in activated BeWo cells (Fig. 1A) , corresponding to the lower inhibition of condition (Fig. 4A) . The inhibitions of carnosine and carnitine in ETV accumulation were aborted in activated BeWo cells (Fig. 3A) , which might be attributed to the down-regulation of PEPT2 and reduced affinity of OCNT2 due to protein phosphorylation (Huang et al., 2009 ). Our study confirmed that mRNA expression of PEPT2 in cytotrophoblasts is higher than that in syncytiotrophoblasts (Berveiller et al., 2015) . The results in PHTCs showed that ENT1 also be involved in the placental transfer (Fig. 7A) , which might be attributed to the higher expression of ENT1 in PHTCs (Fig.   7C ). ENT1 is definitely expressed in placenta and located in brush-border membrane (Barros et al., 1995) , which suggests ENT1 facilitates the transport of ETV across the membrane. ENT2 is also identified in chorionic villi region but its location is not clearly clarified (Govindarajan et al., 2007) .
ETV was proved to be a substrate of hCNT2 and hCNT3 ( Fig. 5C and Fig. 5D ), which was accorded with the recent research showing that CNT2/3 might be involved in the renal reabsorption of ETV (Trejtnar et al., 2016) . Together with the results in PHTCs, we demonstrated that CNT2 and / or CNT3 could contribute to trans-placental passage of ETV. Previous researches (Lu et al., 2004; Yamamoto et al., 2007) and our results (data not shown) demonstrated the mRNA expressions of CNT1/2/3 in human and mouse placenta. However, protein expression of CNTs in human placenta is far less well documented and a consensus has not been reached. Govindarajan et al. reported that no appreciable hCNT1 protein staining is detected in trophoblast layer by in situ bybridization (Govindarajan et al., 2007) , whereas Errasti-Murugarren et al. identified that CNT1 is the only CNT-type protein functionally expressed in human syncytiotrophoblast (Errasti-Murugarren et al., 2011) . However, our results showed the uptake of ETV, a proved substrate of CNT2/3, could be markedly inhibited by phlorizin in PHTCs (Fig. 7A) , which provide the evidence that CNT2 and/ or CNT3 are expressed in human placenta. The above discrepancy might be attributed to individual variation and small sample size used in studies.
Both human and mouse placenta extremely high express OCT3 but with low expressions of OCT1/2 (Kekuda et al., 1998; Lee et al., 2013a) , and OCT3 was reported to be located at the basal membrane of human trophoblasts (Sata et al., 2005) . Our study revealed that ETV is a substrate of hOCT3 (Fig. 6D) . Furthermore, D22 obviously reduced ETV accumulation in PHTCs (Fig. 7A) . Therefore, we concluded that OCT3
contributes to the ETV transfer from fetal to maternal blood. OCTN1/2 are also expressed in human placenta and ETV is a substrate of OCTN1/2 . The results in
PHTCs indicate that OCTN2 but not OCTN1 contributes to the placental transfer of ETV, which might be ascribed to the higher protein expression of OCTN2 in placenta and higher affinity of ETV to OCTN2 . hOAT4 is the highest OATs expressed in placenta whereas hOAT1 and hOAT3 are minimally expressed or even absent (Ugele et al., 2003) . Our study in transfected hOAT4 cells demonstrated that ETV
was not a substrate of OAT4, thus OAT4 was unlikely to mediate ETV transport.
The accumulations of adefovir, emtricitbine and tenofovir in BeWo cells, was less than that of ETV (data not shown), however emtricitabine and tenofovir were reported with high permeation ratio in human placenta (Hirt et al., 2009a; Hirt et al., 2009b) . It might be attributed to the scarce expressions of OATs and OCTs in BeWo cells, because all three drugs were reported to strongly interact with OATs or OCTs (Nakatani-Freshwater and Taft, 2008; Kohler et al., 2011; Maeda et al., 2014) . Therefore, various cell models including BeWo cells, transporter transfected cells, PHTCs and in vivo studies should be comprehensively employed to draw the reasonable conclusion.
Even though ETV is classified as pregnancy category C drug, it is still used in pregnancy and no evidence shows that birth defect is associated with maternal use of This article has not been copyedited and formatted. The final version may differ from this version. ETV during pregnancy. Our results indicate that ETV could cross human placenta but the fetal exposure of ETV in human is low. Therefore, ETV probably could be a candidate for HBV treatment to reduce perinatal transmission at delivery. Our study revealed that multiple transporters are involved in the ETV transport across placenta. The expressions of P-gp and OCT3 at term were reported to be lower than that at preterm (Sun et al., 2006; Lee et al., 2013b) . Therefore, it is necessary to pay attention to the effect of gestation on placental transfer of ETV although antivirals are recommended to reduce perinatal transmission in the third term.
In summary, we showed a comprehensive study of the placental transfer of ETV and revealed that CNT2/3, ENT1/2 and OCTN2 contributed to the ETV uptake from maternal circulation to trophoblast cells, while OCT3 contributed the ETV efflux from trophoblast cells to fetal circulation, and BCRP, MRP2 and P-gp might be involved in the efflux of ETV from trophoblast cells to maternal circulation (Fig. 8) . To further verify the extent of human placental transfer of ETV, ex vivo dually perfused human placenta model should be considered. The safety use of ETV in pregnancy to reduce intrauterine transmission ratio should be concluded from more data from clinical trials in pregnant women. 
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